CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← aTYR PHARMA INC (ATYR) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

aTYR PHARMA INC (ATYR)

Biological Products, (No Diagnostic Substances) · market cap $34M · as of 2026-07-17

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
aTyr Pharma (Nasdaq: LIFE) is a micro-cap biotherapeutics company with a $52M market cap and approximately 55 employees, focused on tRNA synthetase biology. Its lead asset ATYR1940 is in Phase 2 for Facioscapulohumeral Muscular Dystrophy (FSHD), while the company previously described ATYR1923 as its lead ILD candidate — the current pipeline listing centers solely on ATYR1940. With only $10M cash and a stated runway of roughly 2.4 months, the company faces acute near-term financing risk.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
ATYR1940Phase 2Facioscapulohumeral Muscular Dystrophy (FSHD)
EfzofitimodPhase 3SARS-CoV-2 (COVID-19) Severe Pneumonia
Price & technical context
3-month
-81.6%
6-month
-82.6%
12-month
-86.8%
52-wk range
$3.69–$42.00
vs 50-day MA
-59.8%
vs 200-day MA
-83.5%
Realized vol
119.7%
Max drawdown
-91.2%

Daily closes through 2026-11-19. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for ATYR (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.